Recent advances in the treatment of hepatitis C

Abhinav Dhingra, Saloni Kapoor, Saleh Ali Alqahtani

Research output: Contribution to journalArticle

Abstract

Hepatitis C virus (HCV) therapeutics is amidst a revolution. With the recent approval of sofosbuvir (Sovaldi) and simeprevir (Olysio), clinicians and patients started to recognize that for the first time in the history, hepatitis C can be cured in a majority of patients without interferon. These new regimens are safe, and have excellent efficacy and minimal adverse events. Sofosbuvir, a nucleotide analogue (NS5B polymerase inhibitor), is a potent drug with excellent tolerability and pan-genotypic activity with a high barrier to resistance. Simeprevir, a second-generation protease inhibitor which inhibits the initial cleavage of the HCV poly-protein by the NS3/4A protease. Simeprevir has been evaluated in clinical trials in combination with interferon and ribavirin based therapy and also in the COSMO trial in combination with sofosbuvir. More directly acting antiviral therapy drugs are in the pipeline with several drugs being expected to be approved by the FDA in late 2014. Although these drugs have excellent efficacy, they are more costly. The price of these drugs limits treatments of many patients in the world especially in countries with limited economic resources. However, with the availability of a variety of excellent directly acting antivirals (DAAs) in the near future, hopefully many patients would be able to afford the treatment. The future in HCV therapy will focus on special groups of patients who were excluded from initial HCV clinical trials such as post-liver transplant HCV recurrence, patients with HCV/HIV co-infection, and patients with advanced cirrhosis.

Original languageEnglish (US)
Pages (from-to)203-208
Number of pages6
JournalDiscovery medicine
Volume18
Issue number99
StatePublished - 2014

Fingerprint

Hepatitis C
Hepacivirus
Pharmaceutical Preparations
Interferons
Therapeutics
Antiviral Agents
Clinical Trials
Ribavirin
Protease Inhibitors
Coinfection
HIV Infections
Fibrosis
Peptide Hydrolases
Nucleotides
History
Economics
Transplants
Recurrence
Simeprevir
Sofosbuvir

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Recent advances in the treatment of hepatitis C. / Dhingra, Abhinav; Kapoor, Saloni; Alqahtani, Saleh Ali.

In: Discovery medicine, Vol. 18, No. 99, 2014, p. 203-208.

Research output: Contribution to journalArticle

Dhingra, A, Kapoor, S & Alqahtani, SA 2014, 'Recent advances in the treatment of hepatitis C', Discovery medicine, vol. 18, no. 99, pp. 203-208.
Dhingra, Abhinav ; Kapoor, Saloni ; Alqahtani, Saleh Ali. / Recent advances in the treatment of hepatitis C. In: Discovery medicine. 2014 ; Vol. 18, No. 99. pp. 203-208.
@article{50292af077cc4a99b1830ac1e5157210,
title = "Recent advances in the treatment of hepatitis C",
abstract = "Hepatitis C virus (HCV) therapeutics is amidst a revolution. With the recent approval of sofosbuvir (Sovaldi) and simeprevir (Olysio), clinicians and patients started to recognize that for the first time in the history, hepatitis C can be cured in a majority of patients without interferon. These new regimens are safe, and have excellent efficacy and minimal adverse events. Sofosbuvir, a nucleotide analogue (NS5B polymerase inhibitor), is a potent drug with excellent tolerability and pan-genotypic activity with a high barrier to resistance. Simeprevir, a second-generation protease inhibitor which inhibits the initial cleavage of the HCV poly-protein by the NS3/4A protease. Simeprevir has been evaluated in clinical trials in combination with interferon and ribavirin based therapy and also in the COSMO trial in combination with sofosbuvir. More directly acting antiviral therapy drugs are in the pipeline with several drugs being expected to be approved by the FDA in late 2014. Although these drugs have excellent efficacy, they are more costly. The price of these drugs limits treatments of many patients in the world especially in countries with limited economic resources. However, with the availability of a variety of excellent directly acting antivirals (DAAs) in the near future, hopefully many patients would be able to afford the treatment. The future in HCV therapy will focus on special groups of patients who were excluded from initial HCV clinical trials such as post-liver transplant HCV recurrence, patients with HCV/HIV co-infection, and patients with advanced cirrhosis.",
author = "Abhinav Dhingra and Saloni Kapoor and Alqahtani, {Saleh Ali}",
year = "2014",
language = "English (US)",
volume = "18",
pages = "203--208",
journal = "Discovery medicine",
issn = "1539-6509",
publisher = "Discovery Medicine",
number = "99",

}

TY - JOUR

T1 - Recent advances in the treatment of hepatitis C

AU - Dhingra, Abhinav

AU - Kapoor, Saloni

AU - Alqahtani, Saleh Ali

PY - 2014

Y1 - 2014

N2 - Hepatitis C virus (HCV) therapeutics is amidst a revolution. With the recent approval of sofosbuvir (Sovaldi) and simeprevir (Olysio), clinicians and patients started to recognize that for the first time in the history, hepatitis C can be cured in a majority of patients without interferon. These new regimens are safe, and have excellent efficacy and minimal adverse events. Sofosbuvir, a nucleotide analogue (NS5B polymerase inhibitor), is a potent drug with excellent tolerability and pan-genotypic activity with a high barrier to resistance. Simeprevir, a second-generation protease inhibitor which inhibits the initial cleavage of the HCV poly-protein by the NS3/4A protease. Simeprevir has been evaluated in clinical trials in combination with interferon and ribavirin based therapy and also in the COSMO trial in combination with sofosbuvir. More directly acting antiviral therapy drugs are in the pipeline with several drugs being expected to be approved by the FDA in late 2014. Although these drugs have excellent efficacy, they are more costly. The price of these drugs limits treatments of many patients in the world especially in countries with limited economic resources. However, with the availability of a variety of excellent directly acting antivirals (DAAs) in the near future, hopefully many patients would be able to afford the treatment. The future in HCV therapy will focus on special groups of patients who were excluded from initial HCV clinical trials such as post-liver transplant HCV recurrence, patients with HCV/HIV co-infection, and patients with advanced cirrhosis.

AB - Hepatitis C virus (HCV) therapeutics is amidst a revolution. With the recent approval of sofosbuvir (Sovaldi) and simeprevir (Olysio), clinicians and patients started to recognize that for the first time in the history, hepatitis C can be cured in a majority of patients without interferon. These new regimens are safe, and have excellent efficacy and minimal adverse events. Sofosbuvir, a nucleotide analogue (NS5B polymerase inhibitor), is a potent drug with excellent tolerability and pan-genotypic activity with a high barrier to resistance. Simeprevir, a second-generation protease inhibitor which inhibits the initial cleavage of the HCV poly-protein by the NS3/4A protease. Simeprevir has been evaluated in clinical trials in combination with interferon and ribavirin based therapy and also in the COSMO trial in combination with sofosbuvir. More directly acting antiviral therapy drugs are in the pipeline with several drugs being expected to be approved by the FDA in late 2014. Although these drugs have excellent efficacy, they are more costly. The price of these drugs limits treatments of many patients in the world especially in countries with limited economic resources. However, with the availability of a variety of excellent directly acting antivirals (DAAs) in the near future, hopefully many patients would be able to afford the treatment. The future in HCV therapy will focus on special groups of patients who were excluded from initial HCV clinical trials such as post-liver transplant HCV recurrence, patients with HCV/HIV co-infection, and patients with advanced cirrhosis.

UR - http://www.scopus.com/inward/record.url?scp=84925851796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925851796&partnerID=8YFLogxK

M3 - Article

C2 - 25336034

AN - SCOPUS:84925851796

VL - 18

SP - 203

EP - 208

JO - Discovery medicine

JF - Discovery medicine

SN - 1539-6509

IS - 99

ER -